Xiaodong Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiaodong Jiang has a total of 235 co-authors. Here are the top co-authors by number of shared publications:
Chenxi Hu
Department of Oncology, The First People’s Hospital of Lianyungang, Lianyungang City, China
24 shared publications- Kaiyuan Hui
Department of Oncology, The Affiliated Lianyungang Hospital of Xuzhou Medical University, China
18 shared publications Kaiyuan Hui
Department of Oncology, The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, Jiangsu Province, China
15 shared publicationsYun Qiao
Department of Oncology Lianyungang Clinical Medical College Affiliated to Nanjing Medical University Lianyungang Jiangsu Province China
12 shared publicationsChanghong Dong
Department of Oncology, The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, Jiangsu Province, China
8 shared publicationsLei Wang
Department of Oncology The Affiliated Lianyungang Hospital of Xuzhou Medical University Lianyungang Jiangsu Province China
8 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Elsevier in Translational Oncology
- Vol. 73, 103043
HALP score in solid tumors: Prognostic value, heterogeneity, and translational considerations
- 18 September 2026
- Published by Elsevier in Translational Oncology
- Vol. 73, 103043
Open AccessHALP score in solid tumors: Prognostic value, heterogeneity, and translational considerations
- 16 July 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (6) , 10259-10270
An acid-responsive rhodamine-based fluorescent probe for N-terminal protein labeling and aqueous Tsuji–Trost allylic alkylation
The development of acid-responsive fluorescent probes with additional chemical functionality remains of considerable interest in chemical biology. Herein, we report an acid-responsive rhodamine-based fluorescent probe, 2PCA-RhB, which exhibits a pronounced fluorescence “turn-on” response under acidic aqueous conditions through spirolactam ring opening. The probe displays favorable photophysical properties, good aqueous compatibility, and enables fluorescence imaging in living cells. Beyond its fluorescence response, 2PCA-RhB incorporates a 2-pyridinecarboxaldehyde (2PCA) moiety that enables N-terminal-selective protein labeling, while its allyl carbonate functionality is compatible with palladium-catalyzed Tsuji–Trost allylic alkylation under aqueous conditions. These studies establish 2PCA-RhB as an acid-responsive fluorescent probe with both N-terminal labeling capability and compatibility with aqueous transition-metal-mediated transformation. The present work provides a versatile molecular scaffold for the future development of fluorescent chemical tools for protein modification and bioorthogonal applications in complex biological environments.
- 16 July 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (6) , 10259-10270
An acid-responsive rhodamine-based fluorescent probe for N-terminal protein labeling and aqueous Tsuji–Trost allylic alkylation
The development of acid-responsive fluorescent probes with additional chemical functionality remains of considerable interest in chemical biology. Herein, we report an acid-responsive rhodamine-based fluorescent probe, 2PCA-RhB, which exhibits a pronounced fluorescence “turn-on” response under acidic aqueous conditions through spirolactam ring opening. The probe displays favorable photophysical properties, good aqueous compatibility, and enables fluorescence imaging in living cells. Beyond its fluorescence response, 2PCA-RhB incorporates a 2-pyridinecarboxaldehyde (2PCA) moiety that enables N-terminal-selective protein labeling, while its allyl carbonate functionality is compatible with palladium-catalyzed Tsuji–Trost allylic alkylation under aqueous conditions. These studies establish 2PCA-RhB as an acid-responsive fluorescent probe with both N-terminal labeling capability and compatibility with aqueous transition-metal-mediated transformation. The present work provides a versatile molecular scaffold for the future development of fluorescent chemical tools for protein modification and bioorthogonal applications in complex biological environments.
- Open Access
- 11 June 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1837759
Case Report: A rare case of esophageal squamous cell carcinoma with metastases to the pancreas and stomach
Esophageal cancer is a highly aggressive malignancy associated with a generally poor clinical prognosis. While distant metastases are common, the metastasis of esophageal squamous cell carcinoma (ESCC) to the pancreas and stomach is extremely rare. We report the case of a 62-year-old male with a history of ESCC who presented with an incidentally discovered pancreatic mass on imaging 37 months after the completion of radiotherapy. The patient subsequently underwent radical surgical resection. Postoperative histopathological and immunohistochemical analyses confirmed the presence of pancreatic and gastric metastases originating from the primary ESCC. For subsequent disease management, the patient received a systemic regimen comprising immune checkpoint inhibitors combined with platinum-based chemotherapy. This case underscores the importance of considering rare metastases in the differential diagnosis of new pancreatic lesions in patients with a history of ESCC, even following a prolonged disease-free interval. Furthermore, it suggests that aggressive surgical resection combined with postoperative immunochemotherapy may represent a viable multidisciplinary therapeutic strategy for managing such atypical metastatic presentations.
- 11 June 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1837759
Open AccessCase Report: A rare case of esophageal squamous cell carcinoma with metastases to the pancreas and stomach
Esophageal cancer is a highly aggressive malignancy associated with a generally poor clinical prognosis. While distant metastases are common, the metastasis of esophageal squamous cell carcinoma (ESCC) to the pancreas and stomach is extremely rare. We report the case of a 62-year-old male with a history of ESCC who presented with an incidentally discovered pancreatic mass on imaging 37 months after the completion of radiotherapy. The patient subsequently underwent radical surgical resection. Postoperative histopathological and immunohistochemical analyses confirmed the presence of pancreatic and gastric metastases originating from the primary ESCC. For subsequent disease management, the patient received a systemic regimen comprising immune checkpoint inhibitors combined with platinum-based chemotherapy. This case underscores the importance of considering rare metastases in the differential diagnosis of new pancreatic lesions in patients with a history of ESCC, even following a prolonged disease-free interval. Furthermore, it suggests that aggressive surgical resection combined with postoperative immunochemotherapy may represent a viable multidisciplinary therapeutic strategy for managing such atypical metastatic presentations.
- Open Access
First‐line envafolimab plus recombinant human‐endostatin in advanced non–small cell lung cancer with PD‐L1 tumor proportion score ≥1% (Endouble): A multicenter, prospective, single‐arm, phase 2 trial
Background: This trial evaluates the efficacy and safety of combining envafolimab and recombinant human endostatin (Rh‐endostatin) in advanced non–small cell lung cancer (NSCLC). Methods: This trial included treatment‐naive advanced patients with NSCLC with programmed death‐ligand 1 (PD‐L1)–positive and no driver gene mutations. All patients received treatment with envafolimab and Rh‐endostatin every 21 days until disease progression or intolerable toxicity. The primary end points were objective response rate (ORR) and safety. Secondary end points included progression‐free survival (PFS), overall survival (OS), disease control rate (DCR), and duration of response (DOR). An exploratory analysis was conducted to identify biomarkers associated with treatment efficacy. Results: A total of 33 patients were included for efficacy and safety analysis. The ORR was 48.5% (95% CI, 30.8%–66.5%), and the DCR was 81.8% (95% CI, 64.5%–93.0%). The median PFS was 12.3 months (95% CI, 3.1 months–21.5 months). With a median follow‐up of 13.9 months, the median OS was not reached, and the 1‐year OS rate was 73.9%. Treatment‐related adverse events (TRAEs) were observed in 25 (75.8%) patients. Grade ≥3 TRAEs were observed in six patients, and there were no grade 4 or 5 AEs. Based on plasma proteomic analysis, receiver operator characteristic analysis yielded area under the curve (AUC) values of 0.77 (95% CI, 0.61–0.93) for MMP1 and 0.68 (95% CI, 0.49–0.87) for TNFRSF6B. The combined model demonstrated an AUC of 0.81 (95% CI, 0.66–0.96). Conclusions: Envafolimab combined with Rh‐endostatin demonstrated favorable efficacy and tolerable toxicity in patients with PD‐L1–positive, advanced driver‐gene negative NSCLC.
Open AccessFirst‐line envafolimab plus recombinant human‐endostatin in advanced non–small cell lung cancer with PD‐L1 tumor proportion score ≥1% (Endouble): A multicenter, prospective, single‐arm, phase 2 trial
Background: This trial evaluates the efficacy and safety of combining envafolimab and recombinant human endostatin (Rh‐endostatin) in advanced non–small cell lung cancer (NSCLC). Methods: This trial included treatment‐naive advanced patients with NSCLC with programmed death‐ligand 1 (PD‐L1)–positive and no driver gene mutations. All patients received treatment with envafolimab and Rh‐endostatin every 21 days until disease progression or intolerable toxicity. The primary end points were objective response rate (ORR) and safety. Secondary end points included progression‐free survival (PFS), overall survival (OS), disease control rate (DCR), and duration of response (DOR). An exploratory analysis was conducted to identify biomarkers associated with treatment efficacy. Results: A total of 33 patients were included for efficacy and safety analysis. The ORR was 48.5% (95% CI, 30.8%–66.5%), and the DCR was 81.8% (95% CI, 64.5%–93.0%). The median PFS was 12.3 months (95% CI, 3.1 months–21.5 months). With a median follow‐up of 13.9 months, the median OS was not reached, and the 1‐year OS rate was 73.9%. Treatment‐related adverse events (TRAEs) were observed in 25 (75.8%) patients. Grade ≥3 TRAEs were observed in six patients, and there were no grade 4 or 5 AEs. Based on plasma proteomic analysis, receiver operator characteristic analysis yielded area under the curve (AUC) values of 0.77 (95% CI, 0.61–0.93) for MMP1 and 0.68 (95% CI, 0.49–0.87) for TNFRSF6B. The combined model demonstrated an AUC of 0.81 (95% CI, 0.66–0.96). Conclusions: Envafolimab combined with Rh‐endostatin demonstrated favorable efficacy and tolerable toxicity in patients with PD‐L1–positive, advanced driver‐gene negative NSCLC.
- Open Access
- 29 May 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1823046
Case Report: Negative initial endoscopy and 18F-FDG PET/CT may not exclude occult gastric cancer
Gastric cancer with ovarian metastasis (Krukenberg tumor) can mimic primary ovarian malignancy, creating diagnostic uncertainty. We report a female patient with peritoneal dissemination and bilateral adnexal masses, a presentation initially considered more suggestive of primary ovarian malignancy. However, initial EGD showed no definite gastric mass, and 18F-FDG PET/CT revealed no FDG-avid gastric primary lesion. Peritoneal biopsy revealed metastatic adenocarcinoma with a gastrointestinal-favoring immunophenotype, but repeat EGD was initially deferred due to clinical constraints. Empiric ovarian cancer–directed chemotherapy was started, followed by rapid progression. Repeat EGD later revealed an irregular ulcerative lesion at the gastric angle, and biopsy confirmed gastric adenocarcinoma with focal signet-ring cell components.
- 29 May 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1823046
Open AccessCase Report: Negative initial endoscopy and 18F-FDG PET/CT may not exclude occult gastric cancer
Gastric cancer with ovarian metastasis (Krukenberg tumor) can mimic primary ovarian malignancy, creating diagnostic uncertainty. We report a female patient with peritoneal dissemination and bilateral adnexal masses, a presentation initially considered more suggestive of primary ovarian malignancy. However, initial EGD showed no definite gastric mass, and 18F-FDG PET/CT revealed no FDG-avid gastric primary lesion. Peritoneal biopsy revealed metastatic adenocarcinoma with a gastrointestinal-favoring immunophenotype, but repeat EGD was initially deferred due to clinical constraints. Empiric ovarian cancer–directed chemotherapy was started, followed by rapid progression. Repeat EGD later revealed an irregular ulcerative lesion at the gastric angle, and biopsy confirmed gastric adenocarcinoma with focal signet-ring cell components.
- Open Access
- 3 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (14) , eady4536
Tissue-specific inflammation induces cell state plasticity with oncogenic addiction in mucosal melanoma
Mucosal melanoma (MM), an aggressive melanoma subtype arising in mucosal tissues, displays resistance to therapies effective in cutaneous melanoma. To understand how mucosal microenvironment contributes to treatment nonresponsiveness, we performed integrative analysis of single-cell and bulk messenger RNA sequencing data derived from oral mucosa–originated melanoma and revealed that mucosa-specific inflammation induces enrichment of low-pigmented neural crest–like cancer cell, mediated by COX2 + macrophages and their secretome. Maintenance of this inflammation-induced neural crest–like state in cancer cells depends on HER2 and HER3 activation. Inhibition of HER2/3 by pan-HER inhibitors blocks cell state plasticity and overcomes chemoresistance in primary MM cell lines and patient-derived xenograft (PDX) models. These findings provide insights into how the tissue of origin determines cancer aggressiveness, highlight the role of mucosal inflammation in driving melanoma stemness and chemoresistance, and advance the identification of effective treatment options currently lacking for patients with MM.
- 3 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (14) , eady4536
Open AccessTissue-specific inflammation induces cell state plasticity with oncogenic addiction in mucosal melanoma
Mucosal melanoma (MM), an aggressive melanoma subtype arising in mucosal tissues, displays resistance to therapies effective in cutaneous melanoma. To understand how mucosal microenvironment contributes to treatment nonresponsiveness, we performed integrative analysis of single-cell and bulk messenger RNA sequencing data derived from oral mucosa–originated melanoma and revealed that mucosa-specific inflammation induces enrichment of low-pigmented neural crest–like cancer cell, mediated by COX2 + macrophages and their secretome. Maintenance of this inflammation-induced neural crest–like state in cancer cells depends on HER2 and HER3 activation. Inhibition of HER2/3 by pan-HER inhibitors blocks cell state plasticity and overcomes chemoresistance in primary MM cell lines and patient-derived xenograft (PDX) models. These findings provide insights into how the tissue of origin determines cancer aggressiveness, highlight the role of mucosal inflammation in driving melanoma stemness and chemoresistance, and advance the identification of effective treatment options currently lacking for patients with MM.
- Open Access
- 2 April 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1799107
Erythrocyte membrane–liposome coating sustains circulation stability and targeted tumor therapy of CAR-T cells
Background: CAR-T therapy is limited by off-target sequestration in liver, spleen, and lungs, which reduces tumor delivery and risks systemic toxicity. Genetic engineering approaches are complex and carry safety concerns, necessitating efficient non-genetic strategies to optimize CAR-T biodistribution. Purpose: We developed red blood cell membrane–chimeric liposomes (Rlip) as a biomimetic coating system to non-genetically modify CAR-T cells, aiming to enhance immune evasion, prolong circulatory persistence, and redirect trafficking toward tumors while preserving intrinsic effector function. Methods: Rlip-CAR-T cells were prepared via simple incubation. In vitro characterization assessed coating stability, CD47-mediated macrophage resistance, phenotype preservation, and antigen-specific cytotoxicity. In vivo studies evaluated biodistribution, tumor infiltration, and efficacy in Nalm-6 systemic leukemia and 1806-luc subcutaneous ovarian cancer models. Results: Rlip coating stably presented CD47, functionally impairing macrophage phagocytosis and enhancing peripheral persistence without altering memory subsets, activation markers, or cytotoxicity. Rlip-CAR-T cells demonstrated markedly reduced off-target organ accumulation and increased intratumoral enrichment in both models, with superior tumor control and prolonged survival observed in the leukemia model. Conclusions: Rlip surface engineering represents a universal, clinically translatable strategy to overcome CAR-T biodistribution barriers. By integrating erythrocyte-mimetic immune evasion with optimized tumor delivery, this approach improves CAR-T cell accumulation at tumor sites across hematologic and solid malignancies.
- 2 April 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1799107
Open AccessErythrocyte membrane–liposome coating sustains circulation stability and targeted tumor therapy of CAR-T cells
Background: CAR-T therapy is limited by off-target sequestration in liver, spleen, and lungs, which reduces tumor delivery and risks systemic toxicity. Genetic engineering approaches are complex and carry safety concerns, necessitating efficient non-genetic strategies to optimize CAR-T biodistribution. Purpose: We developed red blood cell membrane–chimeric liposomes (Rlip) as a biomimetic coating system to non-genetically modify CAR-T cells, aiming to enhance immune evasion, prolong circulatory persistence, and redirect trafficking toward tumors while preserving intrinsic effector function. Methods: Rlip-CAR-T cells were prepared via simple incubation. In vitro characterization assessed coating stability, CD47-mediated macrophage resistance, phenotype preservation, and antigen-specific cytotoxicity. In vivo studies evaluated biodistribution, tumor infiltration, and efficacy in Nalm-6 systemic leukemia and 1806-luc subcutaneous ovarian cancer models. Results: Rlip coating stably presented CD47, functionally impairing macrophage phagocytosis and enhancing peripheral persistence without altering memory subsets, activation markers, or cytotoxicity. Rlip-CAR-T cells demonstrated markedly reduced off-target organ accumulation and increased intratumoral enrichment in both models, with superior tumor control and prolonged survival observed in the leukemia model. Conclusions: Rlip surface engineering represents a universal, clinically translatable strategy to overcome CAR-T biodistribution barriers. By integrating erythrocyte-mimetic immune evasion with optimized tumor delivery, this approach improves CAR-T cell accumulation at tumor sites across hematologic and solid malignancies.
- Open Access
- 1 April 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (4) , 346
Chemotherapy-free anlotinib-based regimens in advanced non-small cell lung cancer: a real-world retrospective cohort study
Background: Anlotinib is established as a standard later-line treatment for advanced non-small cell lung cancer (NSCLC). However, the real-world efficacy of anlotinib-based chemotherapy-free combinations—particularly in earlier lines of therapy—remains insufficiently characterized. This study aimed to evaluate the survival outcomes of anlotinib monotherapy versus combination regimens and assess the impact of treatment line on efficacy. Methods: In this retrospective, real-world observational study, we analyzed 170 patients with advanced NSCLC. Patients were stratified into three cohorts: anlotinib monotherapy (Group A, n=62), anlotinib plus immunotherapy (Group A+I, n=57), and anlotinib plus targeted therapy (Group A+T, n=51). The primary endpoints were progression-free survival (PFS) and overall survival (OS), analyzed using Kaplan-Meier methods and Cox proportional hazards models. Results: The median PFS and OS for the entire cohort were 10 and 18.5 months, respectively. The objective response rate (ORR) and disease control rate (DCR) for the entire population were 17.6% and 84.8%, respectively. In the subgroups, the ORR was 18.8% (A+I) and 23.1% (A+T) vs. 10.5% (monotherapy), while the DCR was 93.8% (A+I) and 82.1% (A+T) vs. 76.3% (monotherapy). Compared with monotherapy, combination regimens demonstrated superior survival benefits. Specifically, the A+I group showed significantly reduced risks of progression [hazard ratio (HR): 0.461, P=0.001] and mortality (HR: 0.576, P=0.03). Similarly, the A+T group exhibited marked improvements in PFS (median 13.5 vs. 4.0 months; HR: 0.360, Pvs. 10.0 months; HR: 0.332, Pvs. 8.5 months) and OS (37.0 vs. 14.0 months) compared to third-line use. Notably, among patients with driver mutations, the A+T regimen extended median OS to 26.5 months compared to 10.0 months in the monotherapy group. Lack of prior anti-angiogenic therapy was identified as an independent predictor for improved PFS. Conclusions: Anlotinib-based, chemotherapy-free regimens demonstrate significantly greater efficacy than anlotinib monotherapy in advanced NSCLC. Furthermore, the upstream application of these regimens in earlier treatment lines is associated with markedly prolonged survival. These findings support anlotinib-based combinations as a promising chemotherapy-sparing strategy, particularly for patients unsuitable for or refusing chemotherapy.
- 1 April 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (4) , 346
Open AccessChemotherapy-free anlotinib-based regimens in advanced non-small cell lung cancer: a real-world retrospective cohort study
Background: Anlotinib is established as a standard later-line treatment for advanced non-small cell lung cancer (NSCLC). However, the real-world efficacy of anlotinib-based chemotherapy-free combinations—particularly in earlier lines of therapy—remains insufficiently characterized. This study aimed to evaluate the survival outcomes of anlotinib monotherapy versus combination regimens and assess the impact of treatment line on efficacy. Methods: In this retrospective, real-world observational study, we analyzed 170 patients with advanced NSCLC. Patients were stratified into three cohorts: anlotinib monotherapy (Group A, n=62), anlotinib plus immunotherapy (Group A+I, n=57), and anlotinib plus targeted therapy (Group A+T, n=51). The primary endpoints were progression-free survival (PFS) and overall survival (OS), analyzed using Kaplan-Meier methods and Cox proportional hazards models. Results: The median PFS and OS for the entire cohort were 10 and 18.5 months, respectively. The objective response rate (ORR) and disease control rate (DCR) for the entire population were 17.6% and 84.8%, respectively. In the subgroups, the ORR was 18.8% (A+I) and 23.1% (A+T) vs. 10.5% (monotherapy), while the DCR was 93.8% (A+I) and 82.1% (A+T) vs. 76.3% (monotherapy). Compared with monotherapy, combination regimens demonstrated superior survival benefits. Specifically, the A+I group showed significantly reduced risks of progression [hazard ratio (HR): 0.461, P=0.001] and mortality (HR: 0.576, P=0.03). Similarly, the A+T group exhibited marked improvements in PFS (median 13.5 vs. 4.0 months; HR: 0.360, Pvs. 10.0 months; HR: 0.332, Pvs. 8.5 months) and OS (37.0 vs. 14.0 months) compared to third-line use. Notably, among patients with driver mutations, the A+T regimen extended median OS to 26.5 months compared to 10.0 months in the monotherapy group. Lack of prior anti-angiogenic therapy was identified as an independent predictor for improved PFS. Conclusions: Anlotinib-based, chemotherapy-free regimens demonstrate significantly greater efficacy than anlotinib monotherapy in advanced NSCLC. Furthermore, the upstream application of these regimens in earlier treatment lines is associated with markedly prolonged survival. These findings support anlotinib-based combinations as a promising chemotherapy-sparing strategy, particularly for patients unsuitable for or refusing chemotherapy.
- Open Access
- 27 February 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1782198
Case Report: Furmonertinib dose escalation in heavily pretreated EGFR-mutant lung adenocarcinoma with diffuse brain metastases
Furmonertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has demonstrated systemic and central nervous system (CNS) antitumor activity in patients with EGFR-mutant non-small cell lung cancer (NSCLC); however, evidence supporting its use in patients with diffuse brain metastases after multiple lines of therapy and very poor performance status remains limited. Here, we report the case of a 53-year-old man with EGFR L858R-mutant stage IV lung adenocarcinoma who developed multifocal progression involving the lungs, liver, bones, and brain after multiple prior treatments. At admission, he had diffuse brain metastases and an Eastern Cooperative Oncology Group (ECOG) performance status of 4, and he was unable to undergo whole-brain radiotherapy because of impaired consciousness. Dose-escalated furmonertinib was initiated and led to marked relief of neurological and respiratory symptoms within a few days. Subsequent imaging assessments showed sustained clinical benefit, with improvement in performance status and activities of daily living. This case suggests that, in EGFR-mutant advanced NSCLC with extensive CNS progression after multiline treatment failure in whom radiotherapy is not feasible, high-dose furmonertinib may represent a potential salvage option and may help inform individualized treatment strategies in this high-risk population. This single case is hypothesis-generating and larger cohorts/prospective studies are needed to confirm efficacy, safety, and appropriate patient selection.
- 27 February 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1782198
Open AccessCase Report: Furmonertinib dose escalation in heavily pretreated EGFR-mutant lung adenocarcinoma with diffuse brain metastases
Furmonertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has demonstrated systemic and central nervous system (CNS) antitumor activity in patients with EGFR-mutant non-small cell lung cancer (NSCLC); however, evidence supporting its use in patients with diffuse brain metastases after multiple lines of therapy and very poor performance status remains limited. Here, we report the case of a 53-year-old man with EGFR L858R-mutant stage IV lung adenocarcinoma who developed multifocal progression involving the lungs, liver, bones, and brain after multiple prior treatments. At admission, he had diffuse brain metastases and an Eastern Cooperative Oncology Group (ECOG) performance status of 4, and he was unable to undergo whole-brain radiotherapy because of impaired consciousness. Dose-escalated furmonertinib was initiated and led to marked relief of neurological and respiratory symptoms within a few days. Subsequent imaging assessments showed sustained clinical benefit, with improvement in performance status and activities of daily living. This case suggests that, in EGFR-mutant advanced NSCLC with extensive CNS progression after multiline treatment failure in whom radiotherapy is not feasible, high-dose furmonertinib may represent a potential salvage option and may help inform individualized treatment strategies in this high-risk population. This single case is hypothesis-generating and larger cohorts/prospective studies are needed to confirm efficacy, safety, and appropriate patient selection.
- Open Access
- 4 November 2025
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 40 (11)
Delayed Tension Pneumothorax After Microwave Ablation of Lung Metastasis
Microwave ablation, as a minimally invasive treatment, is commonly used for local lung nodules. However, complications such as tension pneumothorax can lead to life-threatening consequences. We present a case of delayed tension pneumothorax that occurred 24 hours post-procedure, which required urgent intervention to prevent further deterioration and reduce mortality risk.
- 4 November 2025
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 40 (11)
Open AccessDelayed Tension Pneumothorax After Microwave Ablation of Lung Metastasis
Microwave ablation, as a minimally invasive treatment, is commonly used for local lung nodules. However, complications such as tension pneumothorax can lead to life-threatening consequences. We present a case of delayed tension pneumothorax that occurred 24 hours post-procedure, which required urgent intervention to prevent further deterioration and reduce mortality risk.